RU2005108992A - Модифицированные сахариды, их конъюгаты и их изготовление - Google Patents

Модифицированные сахариды, их конъюгаты и их изготовление Download PDF

Info

Publication number
RU2005108992A
RU2005108992A RU2005108992/04A RU2005108992A RU2005108992A RU 2005108992 A RU2005108992 A RU 2005108992A RU 2005108992/04 A RU2005108992/04 A RU 2005108992/04A RU 2005108992 A RU2005108992 A RU 2005108992A RU 2005108992 A RU2005108992 A RU 2005108992A
Authority
RU
Russia
Prior art keywords
saccharide
formula
alkyl
capsular saccharide
modified
Prior art date
Application number
RU2005108992/04A
Other languages
English (en)
Russian (ru)
Inventor
Альдо ДЖАННОЦЦИ (IT)
Альдо ДЖАННОЦЦИ
Джованни АВЕРАНИ (IT)
Джованни АВЕРАНИ
Франческо НОРЕЛЛИ (IT)
Франческо НОРЕЛЛИ
Паоло КОСТАНТИНО (IT)
Паоло КОСТАНТИНО
Original Assignee
Чирон Срл (It)
Чирон Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чирон Срл (It), Чирон Срл filed Critical Чирон Срл (It)
Publication of RU2005108992A publication Critical patent/RU2005108992A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2005108992/04A 2002-08-30 2003-09-01 Модифицированные сахариды, их конъюгаты и их изготовление RU2005108992A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0220198.6 2002-08-30
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2008150551/13A Division RU2531909C2 (ru) 2002-08-30 2008-12-19 Модифицированные сахариды, их конъюгаты и их изготовление

Publications (1)

Publication Number Publication Date
RU2005108992A true RU2005108992A (ru) 2005-11-10

Family

ID=9943241

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2005108992/04A RU2005108992A (ru) 2002-08-30 2003-09-01 Модифицированные сахариды, их конъюгаты и их изготовление
RU2008150551/13A RU2531909C2 (ru) 2002-08-30 2008-12-19 Модифицированные сахариды, их конъюгаты и их изготовление

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2008150551/13A RU2531909C2 (ru) 2002-08-30 2008-12-19 Модифицированные сахариды, их конъюгаты и их изготовление

Country Status (16)

Country Link
US (2) US8895516B2 (2)
EP (1) EP1534342B1 (2)
JP (2) JP5268222B2 (2)
CN (2) CN101863998B (2)
AT (1) ATE319481T1 (2)
AU (1) AU2003260921B2 (2)
BR (1) BR0314089A (2)
CA (1) CA2497167C (2)
DE (1) DE60303961T2 (2)
DK (1) DK1534342T3 (2)
ES (1) ES2260682T3 (2)
GB (1) GB0220198D0 (2)
MX (1) MXPA05002315A (2)
NZ (1) NZ538703A (2)
RU (2) RU2005108992A (2)
WO (1) WO2004019992A1 (2)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
WO2005051429A2 (en) * 2003-11-19 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeted conjugates with a modified saccharide linker
MX2007013881A (es) 2005-05-06 2008-10-22 Novartis Vaccines & Diagnostic Inmunogenos para vacunas de meningitides-a.
KR101515078B1 (ko) * 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
WO2010027499A2 (en) 2008-09-05 2010-03-11 University Of Massachusetts Medical School Methods, compositions and vaccines relating to neisseria meningitidis antibodies
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
HUE034251T2 (en) * 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
ES2701169T3 (es) * 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016170186A1 (en) * 2015-04-23 2016-10-27 Synaffix B.V. PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE
JP2019508468A (ja) * 2016-03-15 2019-03-28 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドMsd Wellcome Trust Hilleman Laboratories Pvt.Ltd. 新規の多糖体−タンパク質コンジュゲート及びそれを得る方法
BR112019003992A2 (pt) 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7680185B2 (ja) * 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖-タンパク質コンジュゲートの免疫原性の増強
MX394768B (es) 2017-09-07 2025-03-21 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
MX394767B (es) 2017-09-07 2025-03-24 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
WO2020182635A1 (en) * 2019-03-08 2020-09-17 Glaxosmithkline Biologicals Sa Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
DK0447171T3 (da) * 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
US6472506B1 (en) * 1997-01-21 2002-10-29 Aventis Pasteur S.A. Polysaccharide-peptide-conjugates
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
JP4182269B2 (ja) * 1997-08-08 2008-11-19 ベーリングウエルケ、アクティエンゲゼルシャフト 生体分子のポリサッカライド接合体
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
ES2616180T3 (es) 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Also Published As

Publication number Publication date
BR0314089A (pt) 2005-11-16
WO2004019992A1 (en) 2004-03-11
CA2497167A1 (en) 2004-03-11
CN101863998A (zh) 2010-10-20
EP1534342B1 (en) 2006-03-08
CN1688343A (zh) 2005-10-26
NZ538703A (en) 2006-09-29
JP5268222B2 (ja) 2013-08-21
JP5314745B2 (ja) 2013-10-16
EP1534342A1 (en) 2005-06-01
AU2003260921A1 (en) 2004-03-19
MXPA05002315A (es) 2005-06-08
CA2497167C (en) 2011-07-12
DK1534342T3 (da) 2006-07-10
CN1688343B (zh) 2010-09-08
DE60303961D1 (de) 2006-05-04
CN101863998B (zh) 2012-08-29
DE60303961T2 (de) 2006-10-26
JP2006511465A (ja) 2006-04-06
AU2003260921B2 (en) 2008-03-06
US8895516B2 (en) 2014-11-25
RU2008150551A (ru) 2010-06-27
ES2260682T3 (es) 2006-11-01
US20150166593A1 (en) 2015-06-18
GB0220198D0 (en) 2002-10-09
US20060263390A1 (en) 2006-11-23
ATE319481T1 (de) 2006-03-15
RU2531909C2 (ru) 2014-10-27
JP2012017342A (ja) 2012-01-26

Similar Documents

Publication Publication Date Title
RU2005108992A (ru) Модифицированные сахариды, их конъюгаты и их изготовление
JP2006511465A5 (2)
CA2480389A1 (en) Modified saccharides having improved stability in water
RU2412944C2 (ru) Иммуногены для вакцин против менингита а
JP3310000B2 (ja) 水溶性高分子抗癌剤及び薬物担持用担体
CN110167599B (zh) 包含引入β-半乳糖苷的自我牺牲型连接基团的化合物
US6150341A (en) Vitamin B12 derivatives and methods for their preparation
RU2009130447A (ru) Модифицированные сахариды
JP2010515718A5 (2)
JP2005526153A5 (2)
CA2080891A1 (en) Peg imidates and protein derivatives thereof
US20130116423A1 (en) Synthetic Oligosaccharides for Staphylococcus Vaccine
TW201607557A (zh) 新穎之聚醣共軛物及其用途
FI66878C (fi) Foerfarande foer framstaellning av nya antigenderivat
JPS63190896A (ja) 新規なオリゴ糖、免疫原およびワクチン、ならびにそのようなオリゴ糖、免疫原およびワクチンの製造方法
KR20180121564A (ko) 신규한 다당류-단백질 접합체 및 이의 제조방법
US20210030882A1 (en) Use of bis-iminobiotin compound for drug delivery purposes
WO2012145626A1 (en) Synthetic oligosaccharides for staphylococcus vaccine
CN101108895B (zh) 聚乙二醇乙醛衍生物及其与药物的结合物
RU2338753C2 (ru) Модифицированные сахариды, имеющие улучшенную стабильность в воде
US6765091B1 (en) Oligosaccharides derived from ribose-ribitol-phosphate, and vaccines containing them
EP3491000B1 (en) Stable hydrolysis-resistant synthetic polyribosylribitolphosphate derivatives as vaccines against haemophilus influenzae type b
KR100631855B1 (ko) 신규한 와이-폴리에틸렌글리콜 유도체 및 그의 합성 방법
JP2024180376A (ja) 化合物、免疫増強剤、ワクチン組成物及び粘膜ワクチン組成物
IL323911A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof